The Effect of Lung-Conduction Exercise in Chronic Obstructive Pulmonary Disease (COPD): Randomized, Assessor-blind, Multicenter Pilot Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004724

Enrollment

Registered

2020-02-11

Start date

2019-02-19

Completion date

Unknown

Last updated

2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Behavioral, Others : This randomized, assessor-blind, multicenter trial aims to recruit 54 patients with moderate and severe COPD. Subjects will be randomly allocated to a control group (only medicati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderate and severe COPD patients who diagnosed by forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC) <70 % and 30 % = FEV1 <80 %, aged 40 to 80, had complaints of difficulty in breathing at or above mMRC =2 points, voluntarily agreed to participate in this clinical trial is included.

Exclusion criteria

Exclusion criteria: Have serious respiratory illnesses other than COPD (e.g. lung cancer, pneumonia, active tuberculosis, tuberculosis pulmonary destruction, pneumonectomy, etc.); or with unstable cardiovascular disease (unstable angina, acute myocardial infarction, severe aortic stenosis, etc.) and severe untreated pulmonary hypertension; or with a history of acute deterioration within 2 weeks; or have a change in FEV1 or FVC of 12 % and 200 mL or more for 1 second before or after bronchodilator and attack of asthma; or with other illnesses that may cause death or disability during one year period (e.g. cancer, heart failure, coronary artery disease, cerebrovascular disease, kidney failure, diabetes with severe complications, uncontrolled high blood pressure, etc.); or have difficulty in walking (e.g., cerebrovascular disease, osteoarthritis, and other serious malnutrition); or persons who are unable to understand the consent form or continue the test due to mental retardation or intellectual problems; or pregnant or lactating women; or alcoholics or those with a history of substance abuse; or smoker; or participants who took medication of other clinical trials within 30 days prior to participation in this trial (based on written consent); or with a underlying disease judged by the investigators to be inappropriate for this trial.

Design outcomes

Primary

Measure	Time frame
6-minute walk distance (6MWD)	—

Secondary

Measure	Time frame
Pulmonary function test (FEV1, FVC, FEV1/FVC);Modified Borg scale;mMRC score (modified medical research council);CAT (COPD assessment test);SGRQ (The St. George's Respiratory Questionnaire)	—

Countries

Korea, Republic of

Contacts

Public ContactSu Won Lee

Dunsan Korean Medicine Hospital of Daejeon University

Outcome results